This project has been flagged by a community member as inappropriate due to reason below.*
Expert Interview
Slingshot members are talking to an expert! The topic is:
Evaluation of Sanofi's Amlitelimab Potential in Atopic Dermatitis
Ticker(s): SNYWho's the expert?
Institution: Pennsylvania Centre for Dermatology
- A Board-certified Dermatologist and clinical Associate in the Department of Dermatology at the Perelman School of Medicine at the University of Pennsylvania
- Manage 900 patients with Atopic Dermatitus
- Research focused on evidence-based treatment of skin disease, particularly through participation in clinical studies evaluating emerging therapies.
Interview GoalThis call will be to better understand the landscape of Atopic Dermatitis along with the potential of Sanofi's Amlitelimab
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
